Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3+CD56+ T cells and reversing the exhaustion of PD-1+TIM-3+ T cells in CIK therapy.
- Shaochuan Liu
- Yuan Meng
- Xiubao Ren